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"3% of Americans incarcerated…12 million
released from jails and prisons every year… 35%
of all cases of active tuberculosis identified
among current/recent inmates…500,000 individ-
uals with STDs and 500,000 with latent tubercu-
losis released every year…30% of all Americans
with hepatitis C and 12-18% of those with HIV
pass through our nation's jails and prisons every
year…"
The above excerpt was part of the findings of the
NCCHC/NIJ "Health Status" report released in
May 2002. This national, 3-year-long study was
the largest and most comprehensive of its kind
ever undertaken. With funding from Congress
through the National Institute of Justice, and with
substantial support from the Centers for Disease
Control and Prevention, the National
Commission on Correctional Health Care con-
vened expert panels that included the nation's
most respected researchers, practitioners and
scholars in the fields of public and correctional
health care. The National Institute of Justice
delivered the final report to Congress in May
2002 and is now available on the Internet at
http://www.ncchc.org/pubs_stbr.html. This article
provides highlights of the report and an
abbreviated guide to the management of some of
the infectious diseases facing incarcerated
populations.
HIV/AIDS
The NCCHC/NIJ report estimates that a number
of HIV-infected inmates equivalent to 12% to
18% of the total HIV-infected population in the
U.S. were released from prisons and jails in 1996
(98,000 to 145,000 inmates) and that 35,000 to
47,000 inmates in 1997 were infected with HIV
(estimated rates are higher for releasees than for
current inmates due to the rapid turnover and
short lengths of stay in jails). Considering that
many infected inmates are unaware of their HIV-
positive status - and that jail or prison is often the
first opportunity for routine health care - this
report re-emphasizes the role of the correctional
professional in the detection of new cases of HIV. 
Educate
Correctional health providers are in a key posi-
tion to provide three critical components of HIV
and AIDS prevention: education, testing, and
treatment. HIV testing is available at intake in
most prison and jail settings, although many
newly incarcerated individuals refuse testing at
this juncture. Therefore, HIV testing should be
easily accessible by request in correctional facil-
ities, and should also be offered whenever a con-
dition that might suggest coinfection with HIV is
detected (thrush, shingles, recurrent bacterial
pneumonia, STDs, hepatitis C, etc.) For more
information on conditions that might flag co-infec-
tion with HIV, see the HEPPigram in the
Aug/Sept issue of the HEPP Report (www.hiv-
corrections.org). Counseling and educational
programs, especially peer-led discussions of
condom use and safe injection practices, are key
components of working with inmates to reduce
the risk of acquiring or transmitting HIV once they
are released. 
Diagnose
Acute HIV infection is often mistaken for another
disease or for a minor, self-limited illness.
Patients most commonly present with the follow-
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Table 1: Frequency of Signs and
Symptoms Associated with Acute HIV
Infection1, 2
Signs/Symptoms
Fever
Fatigue
Rash
Lymphadenopathy
Weight Loss
Pharyngitis
Headache
Myalgia / Arthralgia
Nausea, Vomiting, or
Diarrhea
% Patients 
90
80 to 90
40 to 80
40 to 77
70
50 to 73
32 to 70
50 to 70
30 to 60
Continued on page 2
ing signs and symptoms: fever, fatigue,
lymphadenopathy, pharyngitis, rash, and
weight loss (see Table 1). Chronic infection,
depending on the stage, may be symptom-
free. Symptomatic HIV infection should be
treated.
HIV diagnosis is most commonly made with
a routine serology assay (ELISA and con-
firmatory western blot), although several
HIV test technologies have recently been
approved by the FDA for diagnostic use in
the United States. These include rapid
blood, urine and oral fluid tests (for a
list of approved tests, go to
http://www.fda.gov/cber/products/testkits.ht
m). The FDA is soon expected to approve
a fast-response finger-prick HIV blood test,
which requires only a drop of blood and
produces results in less than an hour.
These rapid tests may be particularly use-
ful for jails in relation to occupational expo-
sure to blood from a source of unknown
HIV status, and in follow-up testing of those
who have been exposed to HIV. During
acute seroconversion, the serum ELISA
and western blot are usually negative;
whereas the quantitative HIV viral load will
be positive, and is the diagnostic test of
choice. Approximately 60 or more days
after the acute infection, seroconversion
should occur. All cases of chronic infection
will have a positive HIV ELISA and western
blot.
Treat
Highly Active Antiretroviral Therapy
(HAART) is the standard of care for treat-
ment of HIV infection. There are currently
19 approved antiretroviral agents, each of
which has potential side effects and drug-
drug interactions. Furthermore, HIV treat-
ment recommendations continually evolve.
For these reasons, HIV treatment should
be overseen by clinicians with special
expertise in this disease.3 A recent listing
of HAART doses and side effects and a
discussion of the latest antiretroviral
drugs can be found in the May 2002
HEPP Report and the November 2001
HEPP Report (www.hivcorrections.org). An
update on HIV treatment news from
ICAAC and IDSA will be available in the
December issue of HEPP. For the latest
HIV treatment guidelines, go to
http://hivatis.org/trtgdlns.html#Adult.
Syphilis
Educate
The NCCHC/NIJ report recommends a
strategy of education and screening to pre-
vent and treat highly prevalent infectious
diseases such as syphilis, gonorrhea, and
chlamydia. Rapid screening tests are high-
ly recommended, as they reduce the time
between testing and the start of treatment,
increasing the likelihood that infected
patients will be treated before being
released. 
The CDC recently reported the prevalence
of syphilis in women in three correctional
facilities in the United States to be 35%
of women at intake.4 Figures from the
NCCHC/NIJ report are certainly consistent:
between 46,000-76,000 inmates were
infected with syphilis in 1997. Additionally,
the CDC published newly-updated
"Sexually Transmitted Diseases Treatment
Guidelines" in May 2002, available online
at www.cdc.gov/std/treatment/ default.htm.5
Diagnose
Patients infected with syphilis may present
with symptoms of primary syphilis (ulcer or
chancre at the infection site), secondary
syphilis (skin rash, mucocutaneous lesions
and/or lymphadenopathy), or tertiary
syphilis (cardiac, ophthalmic, auditory
abnormalities, and/or gummatous lesions).
The possibility of HIV infection should be
considered whenever syphilis or any other
STD is diagnosed. Testing for syphilis is
performed routinely in most correctional
facilities. A preliminary diagnosis is made
by non-treponemal tests such as the
Venereal Disease Research Laboratory
test [VDRL] or Rapid Plasma Reagin [RPR]
test.  More specific tests (fluorescent tre-
ponemal antibody absorbed [FTA-ABS]
and T. pallidum particle agglutination [TP-
PA]) are used to confirm infection. Low titer
false-positive nontreponemal test results
are very common in the setting of HIV
infection. 
Treat
The preferred drug for treating all stages of
syphilis is Penicillin G, administered intra-
muscularly (IM). For late latent syphilis or
latent syphilis of unknown duration, the rec-
ommended regimen is benzathine penicillin
G, 7.2 million units total, administered as
three doses of 2.4 million units IM each at
1-week intervals. Treatment of primary
syphilis only requires one dose (2.4 MU
IM). Alternative regimens for penicillin-
allergic patients can be found at
www.cdc.gov/std/treatment/default.htm.6
When syphilis must be treated during preg-
nancy, in a penicillin allergic patient, the
recommendation is to desensitize the
patient (to penicillin) and then follow the
usual penicillin treatment recommenda-
tions. This desensitization should take
place in a hospital as IgE mediated severe
reactions can occasionally occur.
Erythromycin is no longer recommended
for treatment of pregnant women as it is
considered unreliable for cure of the infect-
ed fetus.  
Presumptive treatment for other STDs is
usually carried out in conjunction with treat-
ment for syphilis, since gonorrhea and
chlamydia are "fellow-travelers." For all
patients, including HIV-infected syphilis
patients, careful follow-up of the RPR or
VDRL, which should show decline over
time, is essential. A decline of two tube
dilutions is considered significant and
should be seen by three months post-
treatment. 
Gonorrhea and Chlamydia
Educate
Gonorrhea (GC) and chlamydia are highly
prevalent in correctional populations - the
NCCHC/NIJ report estimates that 18,000
inmates were infected with GC, and 43,000
with chlamydia, in 1997. The CDC report in
1998 documented rates in women of
27% and 8% for chlamydia and GC,
respectively.7
Peer-led educational intervention has been
proven to work in many communities, and
culturally appropriate messages are most
likely to be effective, according to the
NCCHC/NIJ report. The connection
between concurrent STDs and the
increased risk of acquiring or spreading
HIV needs to be clearly explained to
patients to allow them to make informed
decisions to protect their health and the
health of those they care about.8 Both male
and female condoms can be effective in
decreasing the transmission of GC and
chlamydia. Rapid testing methods are cost-
effective and can be invaluable in the
prompt diagnosis of chlamydia and GC.  
Diagnose
Symptoms of GC and chlamydia-related
urethritis and cervicitis can differ for men
and women. Among men, asymptomatic
infections are common. For women, GC is
usually symptomatic, but C. trachomatis is
often asymptomatic and can remain so for
many years. Woman can present with
mucopurulent cervicitis, characterized by a
purulent or mucopurulent endocervical
swab specimen. Woman can also present
with salpingitis or tubo-ovarian abscess.
Ligase chain reactions are simple tests
than can be performed on urine samples
negating the necessity of a pelvic exam in
women or a urethral swab in men.  These
tests are more sensitive than traditional cul-
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The prevalence of AIDS
among inmates is 
five times higher 
than among the
general U.S. population,
according to the 
Report to Congress.
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Dear Correctional Colleagues:
If you've been watching the news on corrections lately, you've seen the newsmedia "spin" on
NCCHC/NIJ Report to Congress that claims "Tens of thousands of inmates are being released
into the community every year with undiagnosed or untreated communicable disease, chronic
disease and mental illness." 
If the truth be known, "The Health Status of Soon-to-be-Released Inmates: A Report to
Congress" doesn't contain any surprises. As correctional health providers, we all know that
infectious diseases are common in correctional settings. What we really need to know is how
to rapidly diagnose the infections, and how to manage them in the correctional setting. 
What's really new about the NCCHC/NIJ Report to Congress is that you now have access to
this report online and that we expect the report to be discussed in detail at the upcoming
NCCHC conference this Fall. We recommend that you visit the NCCHC website
(http://www.ncchc.org/pubs_stbr.html) to download the full report - because our brief review of
the prevalence of the communicable diseases that are described in the report and our accom-
panying "how to" manual on the management of each of these diseases does not do the report
full justice. 
Why do these data deserve re-emphasis? Because they clarify the role of the correctional
health provider on the front line of infectious disease control. Your role is critically important,
not only because you protect your fellow staff and inmates in your institution from communi-
cable disease when you accurately diagnose and treat, but also because in the course of car-
rying out your duties, you protect individuals in the communities to which these patients return.
Our role is to try to provide you with the information and tools you need to carry out your cri i-
cally important job. After reviewing this article, you should be familiar with infectious diseases
that are extremely common in corrections, and should be able to list the methods used to diag-
nose, treatment, and manage these illnesses in correctional settings.
In closing, we want to extend a warm welcome to Beth Herbert, our new Managing Editor. She
comes to us with an extensive writing and editing background and website skills to boot! If this
month's issue is any indication (she started working on it less than four weeks ago) we're in
very capable hands. Welcome Beth! As always, please feel free to contact us with any com-
ments or suggestions. We're also happy to announce that we mark five years of continuou
publication with this issue. We've enjoyed every aspect of writing, editing and publishi g the
HEPP Report over the past five years, and look forward to many more years of service to our
correctional colleagues. 
Sincerely,
Anne S. De Groot, M.D.  Joe Bick, M.D., Co Chief Editors
Letter from the Editor
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4ture techniques for C. trachomatis and are
currently the preferred means of detecting
this organism. If diagnostic tools (e.g., Gram
stain and/or culture) are unavailable, or if
patients are unlikely to return for a follow-up
evaluation, those with classic symptoms
should be considered for empiric treatment
for both GC and chlamydia. 
Treat
Patients infected with N. gonorrhea are often
infected with C. trachomatis, leading to a
recommendation that patients being treated
for gonococcal infection also be treated with
a regimen effective against uncomplicated
genital C. trachomatis infection. Routine
dual therapy without testing for chlamydia
can be cost-effective for populations (such
as inmates) in which dual infection rates are
high (over 10%).
Single-dose regimens should be provided by
directly observed therapy (DOT) to ensure
adherence. The recommended regimens
are ceftriaxone 125 mg IM or cefixime 400
mg po or ciprofloxacin 500 mg po or
ofloxacin 400 mg po PLUS azithromycin 1 g
orally in a single dose or doxycycline 100 mg
orally twice a day for 7 days. These regi-
mens cover both GC and chlamydia.  
Tuberculosis
Educate
According to the Report to Congress, elimi-
nating TB depends heavily on those working
in correctional health care. Coordinated care
and discharge planning to outside health
department or health facilities for continua-
tion of care are paramount in completing
care. Thus educational efforts are best
directed at health care and correctional staff.
Intensified screening, treatment, and con-
tainment efforts among prisoners are vital
components in the CDC's overall plan to
eliminate TB in this country. 
Nationwide, the rate of active TB cases in
the incarcerated is 10-20 times greater than
that in the general U.S. population. An
increasing proportion of TB cases in this
country are developing among the foreign
born. During 2000, a total of 16,377 U.S.
cases of TB were reported - 46% of those
cases among foreign-born persons.9
Foreign born individuals often pass through
correctional facilities if they are detained by
the INS or for other reasons. As with STDs,
screening for TB is usually routine at intake
in jail and prison settings. In addition, cor-
rectional health providers should have a low
threshold for repeating TB screening proce-
dures during incarceration, so as to prevent
repeats of outbreaks of TB in corrections.10
(See the PPD screening HEPPigram in the
March 2002 HEPP Report at www.hivcorrec-
tions.org)
Diagnose
At intake, all inmates should be interviewed
and examined for signs and symptoms con-
sistent with active TB: a productive, pro-
longed cough (a cough lasting for at least 3
weeks), hemoptysis (coughing up blood),
fever, chills, night sweats, easy fatigue, loss
of appetite, or weight loss. Those showing
symptoms should be masked and placed in
negative pressure respiratory isolation until
active TB can be ruled out.  PPD skin testing
should be performed on patients with prior
negative or unknown results; follow-up tests
for individuals who have a positive PPD skin
t st may include posterior-anterior chest
radiographs, sputum-smear and culture
xaminations. TB screening by PPD  is usu-
ally repeated annually in prison settings.
New PPD conversions may signal TB trans-
mission within the facility.
TB can be difficult to diagnose in individuals
infected with HIV, so all HIV-infected per-
sons, regardless of whether they are symp-
tomatic or have a positive skin test, should
also be screened with a chest radiograph.11
Treat
Treatment consists of regimens that include
four drugs at least until drug sensitivity is
available. Isonazide, rifampin (RIF), pyrazi-
namide (PZA), and either ethambutol or
streptomycin are first-line agents (for more
information on managing TB in corrections,
see the March 2002 HEPP Report at
www.hivcorrections.org or http://hivatis.org/
trtgdlns.html#Tuberculosis. Pyrazinamide
and streptomycin should not be used to treat
pregnant women. TB-infected patients who
are HIV-positive and are on a HAART regi-
men containing a PI or an NNRTI may need
to receive rifabutin instead of rifampin, and
may also require dose adjustments in their
HIV medications. HIV infected patients diag-
nosed with active tuberculosis should be
managed by someone expert in manage-
ment of dually infected individuals as the
treatment may become complicated.12,13,14
Since treatment of latent tuberculosis infec-
tion (LTBI) can reduce the risk of active TB
disease developing by approximately 90%,
the CDC and the Institute of Medicine
strongly recommend prophylaxis.15 The rec-
ommended course is INH daily or twice
weekly for nine months. Short course treat-
ments with RIF and PZA or RIF alone can be
used in carefully selected and monitored
patients. Treatment of LTBI will protect not
only corrections but also the communities to
which releasees will return.  
It is critical that inmates being treated for
active TB are on directly observed therapy to
ensure adherence to therapy.  Inadequate or
interrupted treatment can result in relapse,
continued transmission, and the develop-
ment of drug-resistant disease. 
Hepatitis A, B, and C
Hepatitis A
Hepatitis A is usually a self-limited illness
and rarely requires supportive care.
Approximately 33% of adults in the U.S.
have evidence of past infection. There is no
chronic phase of HAV infection. The most
common route of infection is fecal-oral
through contaminated food products, and
sexual transmission, predominately among
men who have sex with men (MSM) and
among intravenous drug users. Though usu-
ally self-limited, HAV has been associated
with severe symptoms, including death, in
the elderly (>55 years) and in persons with
chronic liver disease.  Vaccination is the
most effective means of preventing trans-
mission of hepatitis A. Current vaccines
include TwinRix (combination vaccine for
both hepatitis A and hepatitis B), Havrix, and
Vaqta. 
Hepatitis B
The NCCHC/NIJ report estimated that more
than 36,000 inmates - an estimated 2% of
prison and jail inmates and releasees in
1997 - had current or chronic hepatitis B
infection. Inmates released from prison who
were HBV-positive represented 12% of the
total number of cases in the U.S.
Vaccination against the hepatitis B virus
(HBV), available since 1982, has led to a
decline in the prevalence of HBV in the gen-
eral population. However, 20 to 80% of U.S.
inmates have evidence of past or chronic
HBV infection, and 0.8 - 1.4% of inmates
acquire HBV while in prison.16,17,18High rates
of HBV infection occur in people who have
multiple sex partners and share needles
(including tattooing), and cellmates of
inmates with acute or chronic HBV infection
(analogous to household contacts) are also
at risk for acquiring HBV. Since HIV and
HBV have similar methods of transmission,
coinfection is common.
Educate
While avoiding contact with contaminated
blood, semen, vaginal fluids, and wound
exudates is the only way to be completely
protected against HBV infection, immuniza-
tion is also an effective means of preventing
Health Status Report...
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Improved communication
between corrections and
city and state departments
of health is a key 
component of treating 
and containing infectious
diseases in
prisons and jails.
5infection, particularly among high-risk
groups. Therefore, in a forthcoming issue of
MMWR, the CDC is expected to recommend
that inmates who participate in high-risk
behaviors receive HBV vaccine while incar-
cerated. Recombivax HB and Engerix-B are
two HBV vaccines available in the U.S.
Needle exchange and clean needle pro-
grams are other important interventions that
may reduce HBV risk in the community.
Simultaneous protection against HBV and
HAV can be accomplished with the combi-
nation vaccine, TwinRix.
Diagnose
Only 25 - 50% of cases of acute HBV infec-
tion are symptomatic; the remainder are
asymptomatic or have inconsequential
symptoms. After a one-week to six-month
incubation period, symptoms include
malaise, weakness, anorexia, nausea, vom-
iting, and right upper quadrant pain. The
symptoms abate during the icteric phase
(jaundice), lasting for approximately three
weeks. The hepatic transaminases peak,
and then begin to decline. During the conva-
lescent phase, which may last for up to six
months, symptoms completely resolve. 
Most persons exposed to HBV have a well-
defined immunologic response that results in
the resolution of the infection and protective
immunity. The first serologic marker of HBV
infection to appear is Hepatitis B surface
antigen (HBsAg), a protein on the surface of
the virus. The antigen usually persists in
serum throughout the period of clinical ill-
ness, and is commonly used to diagnose
acute HBV infection. (Please see the
HEPPigram for more information on HBV
serologies during acute and chronic infec-
tion). The presence of anti-HBsAg, also
known as HBsAb, indicates resolution of
acute disease and development of immunity.
Persistent HBsAg suggests the present of
chronic infection.
Treat
While there is no specific therapy for acute
viral hepatitis (other than supportive thera-
py), chronic HBV infections can be treated
with one of three drugs: Interferon,
Lamivudine, or Adefovir. Adefovir (made by
Gilead Sciences Inc. and sold as Hepsera)
was recently given FDA approval. Tenofovir,
approved for use in HIV infection, also has
significant anti-HBV activity.  Patients with
chronic HBV and HIV coinfection are less
likely to respond to interferon treatment for
chronic HBV infection. When lamivudine is
included in an antiretroviral regimen in
patients with HIV and HBV coinfection, HBV
viral replication is often significantly reduced
for the duration of lamivudine treatment. 
The June/July 2001 issue of the HEPP
Report discusses HBV infection in more
depth (www.hivcorrections.org). Guidelines
for treatment of chronic HBV are on the web
at http://www.cdc.gov/ncidod/diseases/
hepatitis/b/index.htm. 
Hepatitis C
HCV is the most common blood-borne infec-
tion in the U.S, with nearly 4.5 million people
infected.19 At least 303,000 - 332,000 prison
and jail inmates were infected with hepatitis
C in 1997, according to the NCCHC/NIJ
report. The 17 to 18.6 % prevalence range of
hepatitis C among inmates - which the study
states may be an understatement - is 9 to 10
times higher than the prevalence of HCV in
the nation's population as a whole. HEPP
Report (www.hivcorrections.org) recently
reviewed the problem of HCV infection in
corrections (March 2002) and new guide-
lines on the treatment of HCV infection
(August 2002). 
Educate
The HCV test results can be used as an
opportunity to educate inmates about the
risks for acquiring HCV (if they are HCV neg-
ative) and the importance of avoiding alco-
hol to prevent progression of the disease, if
HCV is diagnosed. Education also allows
HCV-infected inmates to understand their ill-
ness, take better care of themselves, and
prevent transmission to others.
Diagnose
All inmates should be evaluated for HCV risk
factors; those with HCV risks should be
offered testing. Current FDA-approved
antibody tests for HCV are highly sensitive
and specific (99%), reproducible, and
inexpensive. 
Treat
Most correctional facilities are in the process
of developing protocols for triaging HCV-
infected patients for treatment. Important
changes in the management of HCV infec-
tion are reviewed in the August/Sept issue of
the HEPP Report (www.hivcorrections.org).
Additional information on treating HCV,
including dosing schedules, can be found in
the March 2002 HEPP Report. Updated
guidelines can be found at http://consen-
sus.nih.gov/cons/116/116cdc_intro.htm.
Currently, the best regimen for infected
patients appears to be a 24- or 48-week
course of the combination of pegylated IFN
and ribavirin. 
Conclusion
Whereas the NCCHC/NIJ report might seem
to suggest that correctional health providers
are sending patients home to their commu-
nities with infectious diseases, the problem
is much more complex. Incarceration con-
centrates individuals who have had poor
access to health care and extensive expo-
sure to communicable diseases. Protocols
to address these infections are being devel-
oped and many are already in place.
Appropriate diagnosis and treatment should
be provided, and discharge planning should
be included in the overall plan to treat and
contain infectious diseases. Improved com-
munication between corrections and city and
state departments of health is necessary.
One example of this is illustrated by the New
York City Department of Health involvement
with correctional facilities in its sphere of
influence, local departments of health can
provide important assistance to correctional
facilities by documenting rates of disease in
incarcerated individuals and helping to coor-
dinate the continuation of care and tracking
of contacts within their communities. Much
work remains to be done, of course, but pro-
tocols and procedures can be established to
enable correctional providers to excel in
their roles at the front line of community
health.
Health Status Report...
(continued from page 4)
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Ask the Expert: Case Study: Treatment for Chronic Hepatitis B Infection
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A 40 year-old male is incarcerated for an expected two-year term. At the inmate's intake health assessment the nurse practitioner takes note
that the patient has chronic hepatitis B virus (HBV) infection (surface antigen-positive [sAg+]). He was tested six years ago when he reported to
his primary care doctor with symptoms of acute hepatitis; his liver enzymes were then in the mid 500s. These normalized within six months.
Currently his enzymes are again elevated, with ASTs of 140-164 and ALTs of 111-147. The physical exam shows no obvious indications of chron-
ic HBV and no evidence of cirrhosis. His HBV DNA viral load is 1.2 million copies/ml and he is hepatitis B e-antigen positive (HBeAg). He is HIV-
negative and hepatitis C (HCV)-negative. He denies intravenous drug use, but acknowledges occasional use of crystal methamphetamines and
having two or three drinks per day with occasional binging (on the outside). He feels that completely stopping drinking is an unrealistic expec-
tation for him once he is released. He is very interested in starting treatment and wants to discuss his options.
Discussion:
Q. Is this patient a good candidate for treatment?
A. Yes, this patient is a good candidate for treatment, given the pres-
ence of HBeAg, the elevated ALT, and his motivation to be treated.
Potential treatment endpoints include HBeAg seroconversion, HBV
DNA suppression, liver histologic improvement, and improved clinical
outcome. The presence of HBeAg and HBV DNA indicates active viral
replication, which appears to be associated with an increased risk of
hepatic complications.
A second important factor is the baseline ALT level. For both interfer-
on [3] and lamivudine [4], higher response rates are observed in
patients with elevated ALT. In a two-year study of lamivudine, HBeAg
conversion rates increased with increasing baseline ALT: 7%, 17%,
37%, and 80% for patients with normal, 1-2x normal, 2-5x normal, and
>5x normal baseline ALT, respectively [4].
Finally, the ability to adhere to a daily medication schedule must be
considered. A major drawback of lamivudine therapy is viral resis-
tance. The emergence of viral resistance occurs at a rate of 15% after
one year of therapy, and 69% after five years of therapy [5]. Although
no data has been published linking adherence rates to the develop-
ment of antiviral resistance in hepatitis B therapy, a strong relationship
between adherence and the development of HIV drug resistance has
been reported and therefore should be anticipated for HBV infection
[6]. Furthermore, poor adherence has been linked to drug and alcohol
use [7]. Active drug and alcohol use in this patient may increase his
likelihood of treatment failure. This patient's incarceration, with the
advantage of supervised medication dosing and limited access to alco-
hol, may improve his likelihood of response to oral therapy.
Q. Would you use lamivudine or adefovir (or even tenofovir), or both?
A. The advantages of alpha interferon therapy for the treatment of
chronic hepatitis B should be reviewed. With alpha interferon, the
treatment course is only 4 months, viral resistance is rare, and HBeAg
seroconversion rates are durable. Although HBeAg conversion rates
are low in Asians from endemic areas where vertical transmission is
most common - probably because of immune tolerance [8] - response
rates in patients from non-endemic areas are approximately 33% (end
of treatment responses are approximately 40% but sustained respons-
es only 10% per Lee, et al in NEJM 1997)[9]. Patients treated with
interferon experience symptoms including fatigue, depression, myal-
gias, arthralgias, and hair loss and may also develop laboratory abnor-
malities such as pancytopenia. However, for those who can tolerate
these side effects, interferon may still be the best option for treatment
of chronic hepatitis B. Initial treatment with interferon also preserves
the availability of lamivudine for use in a pre-transplant setting, when
potent suppression of HBV DNA is necessary [10].
Unlike lamivudine, adefovir dipivoxil, recently approved by the FDA,
does not appear to be associated with a high rate of HBV resistance.
Although data beyond one year is not yet available, no resistance
mutations to adefovir dipivoxil were observed among 381 genotyped
patients after 48 weeks of treatment [11]. HBeAg conversion rates
have been reported as 12% after 48 weeks [12]. Because of  the lower
resistance rates associated with adefovir, long-term treatment with this
compound may be more feasible.
No studies have been done examining the efficacy and safety of
lamivudine and adefovir combination treatment versus adefovir
monotherapy. Because of the theoretical benefit of increased antiviral
potency with combination therapy, lamivudine and adefovir would be
favored. No studies have been done comparing adefovir to tenofovir,
a drug that has recently been released for HIV treatment, and also has
anti-HBV activity. There are no clear advantages to using tenofovir ver-
sus adefovir, but the two should not be used together.
Q. Is treatment lifelong?
A. In lamivudine-treated patients who do not achieve e-antigen sero-
conversion, viral rebound occurs shortly after treatment discontinua-
tion, and is often accompanied by a hepatitis flare [13]. Several stud-
ies have reported that lamivudine-induced HBeAg seroconversion is
durable, and that treatment can be discontinued [14]. However, a
recent South Korean study reported a relapse rate of 57% in patients
who achieved HBeAg seroconversion, raising the possibility that
relapse may occur more frequently in individuals with vertically trans-
mitted infection [15].
For this patient with adult-acquired infection, treatment should contin-
ue until viral resistance or HBeAg seroconversion occurs. If viral resis-
tance does not occur, treatment should continue indefinitely for eAg
positive hepatitis, as long as the drug is being tolerated.
Q. What parameters should be followed on treatment?
A. Lamivudine is generally well tolerated, but has rarely been associ-
ated with anemia, neutropenia, and pancreatitis. For adefovir, renal
insufficiency was observed primarily at doses of 60 mg or greater. At
the approved 10 mg dose, renal insufficiency has not been observed.
Because little experience with lamivudine/adefovir combination thera-
py for chronic hepatitis B has been reported, monitoring should occur
more frequently during the initial treatment period. Recommended
laboratory monitoring for safety include a complete blood count, amy-
lase, liver enzymes, and renal function tests at 1 month, 3 months, 6
months, 9 months, and 12 months. Efficacy can be monitored every 6
months with liver function tests, HBeAg, and HBV DNA levels.
Q. Should the patient have a liver biopsy? This particular inmate is in
a remote correctional facility, far from a GI specialist.
A. Liver biopsies are useful when patients are undecided about thera-
py. For example, liver biopsies are particularly useful in assessing
genotype 1 hepatitis C, because the one-year treatment course with
pegylated interferon/ribavirin is associated with only a 50% response
rate and substantial side effects [17]. A liver biopsy may be useful in
hepatitis B, particularly in the setting of a normal baseline ALT, when
treatment-induced HBeAg conversion rates are low. Because liver
enzymes are poorly correlated with histologic findings, liver biopsies
are helpful in defining prognosis for patients with either normal or ele-
vated ALT [18]. An estimated 15-30% of patients with normal serum
ALT may have substantial piecemeal necrosis on liver biopsy [19]. For
patients without hepatic fibrosis, the natural history of disease could be
benign, and should be weighed against the cost, inconvenience, and
potential side effects of antiviral therapy. As new agents are being
developed, patients with benign liver biopsies may opt to defer treat-
ment until more effective agents are available.
If the patient and/or the provider is hesitant to begin treatment because
of the concern of side effects or lack of compliance (relapse to drug or
alcohol use when released from prison), and they need more informa-
tion on which to base a decision, then I would recommend biopsy. In
Continued on page 7
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There are now three FDA-approved treatments for the management of chronic HBV infection: lamivudine, interferon alfa-2b, and, most
recently approved, adefovir dipivoxil. Adefovir dipivoxil is the first nucleotide analogue to receive FDA approval for the treatment of
chronic hepatitis B.   
The recommended treatment strategies are:1
w Antiviral therapy should be given to patients with active replicative HBV disease
w To minimize the risk of lamivudine resistance, a regimen containing lamivudine plus adefovir dipivoxil or tenofovir DF should 
be considered in antiretroviral- and anti-HIV-naive patients
w Treatment should be continued in patients already receiving lamivudine monotherapy
w Adefovir dipivoxil is effective for patients with lamivudine-resistant HBV
Antiviral Agents for the Treatment of Hepatitis B
HBV 101: New Treatments for Hepatitis B
this particular case, given that this patient is motivated to be treated,
will be able to be monitored regularly, and is likely to be compliant with
the treatment - at least for the anticipated two years of incarceration -
I would be open to treating without biopsy.
Q. Should he receive a hepatitis A virus (HAV) vaccine? And, what
would be the rationale either way?
A. Yes, he should be vaccinated against HAV. An increased risk of ful-
minant liver failure from hepatitis A infection has been reported in
patients chronically infected with hepatitis B and C [20, 21, 22]. Cost-
effectiveness analysis of hepatitis A vaccination in patients with chron-
ic hepatitis C have yielded conflicting results [23, 24]. Similar studies
have not been performed for hepatitis B. Nevertheless, the Centers for
Disease Control recommends hepatitis A vaccination for individuals
with chronic liver disease [25].
Q. If this patient decides to defer treatment, how should he be monitored?
A. Current recommendations for patients with chronic hepatitis B are
to screen for hepatocellular carcinoma every 6 months with an ultra-
sound and alpha-fetoprotein level after the age of 35. Such screening
has been shown to be cost-effective in preventing death from hepato-
cellular carcinoma [26]. Serial liver enzyme measurements can be per-
formed on the same schedule to detect episodic flares, which may
occur with or without HBeAg seroconversion. The frequency and dura-
tion of flares without HBeAg seroconversion have been related to the
likelihood of developing clinical complications of chronic hepatitis B [8].
Frequent or prolonged flares would be an indication to recommend
treatment.
DISCLOSURES:* Nothing to disclose
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NAME
Adefovir dipivoxil
Lamivudine
Interferon-alfa-2b
Tenofovir disoproxil
fumarate
Emtricitabine
L-dT
ACTIVITY
Inhibits HIV reverse transcriptase
and HBV DNA polymerase
Inhibits HIV reverse transcriptase
and HBV DNA polymerase
Antiviral and immunomodulatory
effects
Inhibits HIV reverse transcriptase
(FDA-approved) and HBV DNA
polymerase
Inhibits HIV reverse transcriptase
and HBV DNA polymerase
Inhibits HBV DNA polymerase
only
KEY FINDINGS
w Used at lower doses than were studied for HIV
w Produced -4.80 log10 copies/mL reduction in HBV DNA (9/35 patients
undetectable) at week 72 among lamivudine-resistant patients
w 9% HBeAg seroconversion rate
w Monotherapy (100 mg/day) associated with HBV DNA clearance or reduc-
tion in nearly all patients
w HBeAg seroconversion in only 17% at 1 year
w YMDD mutants are lamivudine-resistant, but probably replication-impaired
w Lamivudine withdrawal may result in severe hepatic flares
w Compared with lamivudine, comparable clinical response rates and higher
HBeAg seroconversion and HBsAg clearance rates
w Poor results in perinatally acquired disease and among Asian patients
w Superior efficacy and reduced toxicity of pegylated forms of interferon
w Active against HBV at doses used to treat HIV
w Produced -3.94 log10 copies/mL reduction in HBV DNA at 48 weeks
among 12 lamivudine-resistant patients
w 1/12 HBeAg seroconversion
w 61% undetectable HBV DNA at 1 year at 200 mg/day, and 50% HBeAg
seroconversion
w Up to 3.6 log10 copies/mL reduction in HBV DNA at 4 weeks among
patients with wild-type HBV
FDA-Approved Anti-HBV Agents
Investigational Anti-HBV Agents
1. Chung, R. New Developments in the Management of Hepatitis B Virus/HIV Coinfection. Medscape HIV/AIDS eJournal 8(5), 2002.
Ask the Expert... (continued from page 6)
40th Annual Infectious Disease
Society of America (IDSA)
Meeting
October 24-27, 2002
Chicago, Illinois
Call: 703.299.0200
Email: info@idsociety.org
Visit: http://www.idsociety.org/
ME/AM2002/ToC.htm
4th Annual National
Corrections Telemedicine
Conference
November 24-26, 2002
Tucson, Arizona
Call: 520-626-4785
Email: hatheway@u.arizona.edu
Visit: http://www.nctc2002.com/
North American AIDS
Treatment Action Forum
December 8-11, 2002
New Orleans, Louisiana 
Fee: before Nov. 8, 
$150 members
$175 non-members
After Nov. 8, $225
Call: Paul Woods,
202.483.6622 ext. 343
Email: pwoods@nmac.org
Visit: www.nmac.org/nataf/2002
Hepatitis C Management 
For Prisoners
(pre-conference meeting)
January 25-26, 2003
San Antonio, Texas
Visit: http://www.med.umn.edu/
cme/Html/Hepcoordinators.html
National Hepatitis
Coordinators' Conference
January 26-30, 2003
San Antonio, Texas
Fee: $125
Call: 800.776.8636
Visit:  http://www.med.umn.edu/
cme/brochures2002/hepco-
ord2003/hepcoordbro2003.html
15th National HIV/AIDS 
Update Conference
Focusing on the Front Lines:
Practical Lessons in Prevention,
Treatment, and Care
March 30-April 2, 2003
Miami, Florida
Scholarships available
Email: nauc@total.net
Visit: http://www.amfar.org/nauc
Save the 
Dates
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HIV
Once a Day Dosing Approved for Epivir
(lamivudine)
The FDA has approved an expanded label indi-
cation for GlaxoSmithKline’s Epivir (lamivudine),
to be used once daily to treat HIV infection in
combination with other antiretroviral agents. The
recommended oral dose of Epivir for adults is
300 mg daily, administered either as 150 mg
twice daily or 300 mg once daily.
FDA, 7/2/02, http://hivatis.org/newdose.html
Changes in Agenerase Product Labeling
The product labeling for Agenerase (amprenavir)
has been changed to reflect new precautions
related to the use of the drug with methadone
and with oral (hormonal) contraceptives. The
complete Agenerase label can be found at
http://www.fda.gov/cder/foi/label/2002/21007s11
,21039s10lbl.pdf. FDA, 8/12/02.
HCV
FDA Approves Adefovir for Chronic
Hepatitis B
The FDA has approved the antiviral agent ade-
fovir dipivoxil for the treatment of chronic
Hepatitis B. Adefovir dipivoxil, made by Gilead
Sciences Inc. and sold as Hepsera, is the first
nucleotide analogue to receive FDA approval to
treat chronic HBV. The drug, administered as a
10 mg oral tablet, also proved effective in
patients who were resistant to lamivudine.
FDA Talk Paper, 9/20/02, www.fda.gov/bbs/top-
ics/ANSWERS/2002/ANS01163.html
Trial to Study Hepatitis C in African
Americans
NIH has enrolled 400 adult patients - 200 African
Americans and 200 white Americans - in a study
of viral resistance to antiviral therapy for chronic
hepatitis C. All participants will receive a course
in the combination of peginterferon alfa-2a and
ribavirin. Particular emphasis will be placed on
determining why some patients respond more
positively to therapy than others. A website
describing the trial will be available at
http://www.edc.gsph.pitt.edu/virahepc.
Hepatology, Sept. 2002, Vol. 36(3)
Effort Made to Inform Inmates of HCV status
in NJ Prisons
New Jersey corrections officials launched a
mass notification program to inform HCV-posi-
tive inmates of their diagnosis. According to a
medical audit, all 1,169 prisoners in the state
who are known to have the disease have been
informed of their disease status. While most
inmates receive their diagnosis within a year of
being tested, 121 waited between one and two
years to be informed. Twenty-one inmates who
tested positive for HCV were recently released
from prison without being informed of their diag-
nosis. Although NJ estimates that 5% of prison-
er  in the state have hepatitis C, the state does
not currently provide treatment for that disease.
Philadelphia Inquirer, 10/6/02
HCV/HBV and HIV Coinfection
New Safety Information for Videx
(Didanosine, ddl) used with Ribavirin
The Videx (Didanosine, ddl) label has been
revised to include new, precautionary informa-
tion about co-administration of Videx and rib-
avirin (RBV) in HIV/HCV co-infected patients.
The new label includes the warning that "Co-
administration of ribavirin with Videx should be
undertaken with caution, and patients should be
m nitored closely for didanosine-related toxici-
ties. Videx should be suspended if signs or
symptoms of pancreatitis, symptomatic hyper-
lactatemia, or lactic acidosis develop."
FDA, 9/25/02, http://hivatis.org/videx.html
ICAAC Report on the use of Tenofovir on
HIV- and HBV-infected persons
At the 42nd ICAAC meeting in San Diego,
researchers reported on the use of tenofovir in
HIV/HBV co-infected patients. In the test, 18
patients received the standard dose of 300mg of
tenofovir once daily as part of their HIV regimen.
During the study period, two patients converted
t  e antibody positive, and none of the patients
l st HIV virological control as a result of the teno-
fovir. The authors concluded that tenofovir is
active against HBV when used in HIV-positive
individuals.
ICAAC Conference Report (all reports archived
at http://www.natap.org)
Inside News
Resources & Websites
CDC Recommendations and Guidelines
Division of HIV/AIDS Prevention
http://www.cdc.gov/hiv/pubs/guidelines.htm 
MEDLINE plus: Hepatitis B 
http://www.nlm.nih.gov/medlineplus/hepatitisb.html
NIH Hepatitis Consensus: Management of
Hepatitis C
http://consensus.nih.gov
CDC: Sexually Transmitted Disease
Guidelines, 2002
http://www.cdc.gov/std/treatment
CDC Division of Tuberculosis Elimination
http://www.cdc.gov/nchstp/tb/
Canadian HIV/AIDS Policy and Law Review
2002
ht p://www.aidslaw.ca/Maincontent/otherdocs/
Newsletter/vol7no12002/issue.htm
Canadian resource on HIV/AIDS and prisons
PROS & CONS: A Guide to Creating
Successful Community-based HIV/AIDS
Programs for Prisoners By Rick Lines
To obtain a free copy (plus postage) call
877.999.7740, email aidssida@cpha.ca, or go to
www.clearinghouse.cpha.ca
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through April 30, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  A high percentage of patients with acute HIV infection com-
monly present with the following signs and symptoms:
a) Fever
b) Lymphadenopathy
c) Weight loss
d) All of the above
e) None of the above
2. The preferred drug for treating all stages of syphilis is:
a) Acyclovir
b) Doxycycline
c) Penicillin G
d) Ceftriaxone
3. Symptoms of N. gonorrhoeae and C. trachomatis-related ure-
thritis and cervicitis are similar, and easily detectable, in both
men and women.
a) True
b) False
4. Acceptable treatments for a patient who has both gonorrhea
and chlamydia are:
a) Ceftriaxone 125 mg IM and Penicillin G 7.2 MU IM
b) Ciprofloxacin 500 mg po and azithromycin 1200 mg po
c) Penicillin G 7.2 MU IM
d) Ceftriaxone 125 mg IM and doxycycline 100 mg po bid
5. The immediate response to patients showing TB symptoms
should be:
a) Respiratory isolation and posterior-anterior chest 
radiographs
b) Sputum-smear and culture examinations
c) Respiratory isolation and PPD skin testing
d) Sputum-smear and culture examinations and posterior-
anterior chest radiographs
6. What percentage of acute HBV cases is symptomatic?
a) 25 - 50%
b) 50 - 75%
c) 10 - 20%
d) 25 - 30%
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HBV 101 5  4  3  2  1   5  4  3  2  1  
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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